FY2017 $10 Million KCRP Program Awardees
Jay to check all links. SM to change subheads to be consistent. The following are the awards announced by the Department of Defense Kidney Cancer Research Program (KCRP) for Federal Fiscal Year 2017. This is the first year of KCRP’s existence. We are showing the awardees for this $10 million program to distinguish it from the previous years’ grants under the PRCRP when kidney cancer researchers received an average of $1 million per year. Now, in FY2022, KCRP grants totaled $50 million, or five times the initial FY2017 funding.The following are the awards announced by the Department of Defense Kidney Cancer Research Program (KCRP) for Federal Fiscal Year 2017.
This program is the result of Action to Cure Kidney Cancer’s lobbying campaign. The awards were finalized fall 2018, when negotiations between DoD and the awardees and their institutions were completed.
Link to view KCRP public and technical research abstracts.
Consortium Development Award
| Institution | Principal Investigator | Project | Amount |
|---|---|---|---|
| MD Anderson Cancer Center | Eric Jonasch | Kidney Cancer Clinical Trials Consortium | $1,000,000 |
Investigators at or above Assistant Professor (or equivalent)
- Supports infrastructure development to establish the necessary collaborations among a Coordinating Center and Clinical Sites
- Multi-institution collaboration required
- Supports clinical trials of novel interventions with the potential to have a significant impact on patient care in kidney cancer
- Proposed trials may be Phase 0, Phase 1, or Phase 2
- Minimum of three separate institutes: one Coordinating Center and at least two Clinical Sites (other than the Coordinating Center)
- Awardee will be eligible to apply for FY19 Consortium Award, if funds are available
- Maximum funding of $1.6 million total cost
- Maximum period of performance is 2 years
Idea Development Award — Established Investigator
| Institution | Principal Investigator | Project | Amount |
|---|---|---|---|
| Dana-Farber Cancer Institute | Wayne Marasco | CAR T-Cells and the Tumor Microenvironment | $698,272 |
| Indiana University at Indianapolis | Roberto Pili | Targeting TFE3 in Translocation RCC | $630,000 |
| Institute for Cancer Research | Vladimir Kolenko | Histone-Dependent PARP-1 Inhibitors for the Treatment of RCC | $566,149 |
| Maine Medical Center | Leif Oxburgh | Modeling the Effects of Stroma on Clear Cell RCC | $553,824 |
Investigators at or above Assistant Professor (or equivalent)
- Independent investigators 10 years or more from a terminal degree
- Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer
- Preliminary data is required; need not be in kidney cancer
- Innovation and impact are the most important review criteria
- Clinical trials are not allowed
- Maximum funding of $400,000 in direct costs (plus indirect costs)
- Period of performance not to exceed 3 years
Idea Development Award — Early Career Investigator
| Institution | Principal Investigator | Project | Amount |
|---|---|---|---|
| Dana-Farber Cancer Institute | Kathleen Mahoney | VISTA:VSIG3 an Actionable Immune Checkpoint Target in Kidney Cancer? | $425,000 |
| University of Texas Southwestern | Laura Banaszynski | Chromatin Dysregulation and Metabolism Disorder in Kidney Cancer | $647,999 |
| Vanderbilt University | John Wilson | Reinvigorating Antitumor Immunity in RCC with Nanoparticulate STING Agonists | $628,000 |
| Wayne State University | Arun Iyer | Tumor Penetrating Oligomicelles to Reverse Drug Resistance and Immune Modulation in RCC | $611,475 |
Investigators at the level of Assistant Professor, Instructor, or Assistant Research Professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or family medical leave) at the time of application submission deadline
- Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer
- Preliminary data is required; need not be in kidney cancer.
- Innovation and impact are the most important review criteria.
- Clinical trials are not allowed
- Maximum funding of $400,000 in direct costs (plus indirect costs)
- Period of performance not to exceed 3 years
Concept Award
| Institution | Principal Investigator | Project | Amount |
|---|---|---|---|
| Baylor College of Medicine | Durga Tripathi | Reading the SETD2 Methyl Mark on Microtubules | $118,861 |
| Beth Israel Deaconess Medical Center | Chun-Hau Chen | Identification of a New Immune Checkpoint Pathway in RCC | $131,250 |
| Duquesne University | Wilson Meng | Antitumor Immunity in RCC by Injection of Anti-PD-1 Antibody and Adenosine Deaminase | $100,791 |
| Glycomantra, Inc. | Hafiz Ahmed | Personalized Cellular Immunotherapy for Kidney Cancer | $103,013 |
| Memorial Sloan Kettering Cancer Center | Eduard Reznik | Single Cell Architecture of Mitochondrial DNA Mutations in Renal Cell Carcinoma | $128,775 |
| National Cancer Institute | Catherine Callahan | Do Polyfluoroalkyl Chemicals (PFCs — Used to Make Teflon) Contribute to the Development of RCC? | $89,700 |
| MD Anderson Cancer Center | Nizar Tannir | A Novel Mechanism of Pathogenesis for Renal Medullary Carcinoma | $120,000 |
| University of Louisville | Paula Bates | Combining Immunotherapy with Nanoparticles for Improved Kidney Cancer Outcomes | $115,500 |
| University of North Carolina | Hongwei Du | Targeting B7-H3 in Metastatic Renal Cell Carcinoma Using CAR T-Cells | $116,625 |
Investigators at All Academic Levels
- Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer
- Emphasis on innovation
- Clinical trials not allowed
- Preliminary data not allowed
- Blinded review
- Maximum funding of $75,000 for direct costs (plus indirect costs)
- Maximum period of performance is 1 year
Translational Research Partnership Award
| Institution | Principal Investigator | Project | Amount |
|---|---|---|---|
| Brigham and Women’s Hospital | Sabina Signoretti | Predictive Biomarkers for Nivolumab Treatment in Metastatic Renal Cell Carcinoma (Partnership #1) | $392,010 |
| Dana-Farber Cancer Institute | Toni Choueiri | Predictive Biomarkers for Nivolumab Treatment in Metastatic Renal Cell Carcinoma (Partnership #1) | $672,464 |
| Dana-Farber Cancer Institute | Catherine Wu | Using Single Cell Transcriptomics to Understand Tumor & Immune Heterogeneity Driving Resistance and Rationally Select Immune Therapy in Advanced RCC (Partnership #2) | $837,705 |
| Georgetown University | Michael Atkins | Using Single Cell Transcriptomics to Understand Tumor & Immune Heterogeneity Driving Resistance and Rationally Select Immune Therapy in Advanced RCC (Partnership #2) | $194,963 |
Investigators at or above Assistant Professor (or equivalent)
- Supports partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications
- Supports translational correlative studies
- Preliminary data required
- Funding for clinical trials not allowed
- Maximum funding of $600,000 for direct costs (plus indirect costs)
- Maximum period of performance is 3 years
NB: Identification on the list of applications recommended for funding is not intended to either confer a right to funding nor does it guarantee funding. The award of federal funds to support any of these applications is contingent upon successful negotiations and applicable federal policy.